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Comparison of light emitting diode phototherapy
and double standard conventional phototherapy for
nonhemolytic neonatal hyperbilirubinemia
Aim: To compare the efficacies and the rebound bilirubin levels of infants who received light
emitting diode phototherapy and double standard conventional phototherapy.
Materials and Methods: One hundred twenty-three healthy term and near term (≥35 weeks)
infants requiring phototherapy for non-hemolytic hyperbilirubinemia were enrolled in the study.
All infants’ gestational age, type of feeding, age at phototherapy, total serum bilirubin level at
initiation and termination of phototherapy, duration of phototherapy, rebound TSB levels, and
type of phototherapy were recorded. Fifty-four patients received double standard conventional
phototherapy (Group I) and 69 patients received light emitting diode phototherapy (Group II).
Rebound total serum bilirubin levels after 24-48 h were compared in both groups. Infants with
rebound bilirubin values greater than or equal to concentrations before phototherapy was again
exposed to phototherapy.
Results: Group I consisted of 54 patients whereas Group II included 69 patients. A decrease in
bilirubin concentration occurred in all infants but was especially marked in the infants exposed to
light emitting diode phototherapy. There was no significant difference in rebound total serum
bilirubin levels between the groups.
Conclusions: Light emitting diode phototherapy was more effective than double standard
conventional phototherapy in the treatment of non-hemolytic hyperbilirubinemia in newborns.
Key Words: Intensive phototherapy, newborn, rebound bilirubin, double conventional
phototherapy

Neonatal hiperbilirübünemide yoğun fototerapi ile standart ikili
konvansiyonel fototerapinin karşılaştırılması
Amaç: Yoğun fototerapi ile ikili standart konvansiyonel tedavinin etkinliğini ve rebound bilirubin
düzeyine etkisini fototerapi alan yenidoğanlarda karşılaştırmak.
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Yöntem ve Gereç: Hemolitik olmayan hiperbilirübinemisi olan ve gestasyonel yaşları 35 hafta ve
üzerinde olan 123 bebek bu çalışmaya alındı. Bütün bebeklerin gestasyonel yaşları, beslenme
şekilleri, fototerapi almaya başladıklarında kaç günlük oldukları, fototerapi başlangıcında ve
bitiminde total bilirübin düzeyleri, fototerapi alma süreleri, rebound total serum bilirubin
düzeyleri ve hangi fototerapi şeklini aldıkları kaydedildi. Bu hastaların 54’ü ikili standart
konvansiyonel fototerapi (Grup I) almışken 69’u da yoğun fototerapi (Grup II) aldı. Her iki grupta
da tedaviden 24-48 saat sonra rebound total serum bilirubin düzeyleri karşılaştırıldı. Eğer
bebeklerin rebound serum bilirubin düzeyleri fototerapi öncesi bilirübin düzeylerine eşit ya da
fazlaysa tekrar fototerapi verildi.
Bulgular: Grup I’ de 54, Grup II’de 69 hasta vardı. Bütün bebeklerde serum bilirübin düzeyleri
düşerken yoğun fototerapi alan hastalarda bu düşüş daha belirgindi. Her iki grupta da rebound
serum bilirubin düzeyleri arasında fark yoktu.
Sonuç: Bu çalışmada non-hemolitik hiperbilirubinemisi olan yenidoğanlarda yoğun fototerapinin
ikili standart konvansiyonel fototerapiye gore daha etkin olduğu bulunmuştur.
Anahtar Sözcükler: Yoğun fototerapi, yenidoğan, rebound bilirubin, ikili standart konvansiyonel
fototerapi
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Introduction
Phototherapy is the accepted method of treating
neonatal jaundice, its clinical efficacy having been
confirmed in many studies (1,2). Although
phototherapy is highly efficacious in the majority of
infants presenting with neonatal jaundice, it is well
known that phototherapy using daylight lamps is
occasionally not effective, especially in cases of
severe or rapidly increasing jaundice. In such
situations, the use of high-intensity phototherapy to
ensure greater effectiveness and a faster rate of
decrement in bilirubin levels would be useful (1).
Since this type of phototherapy produces a more
rapid decline in the total serum bilirubin (TSB) level
than conventional phototherapy, it is possible that a
greater rebound might occur (3). Although intensive
phototherapy has been used in Turkey since 2005,
most centers do not have it. Therefore, double
standard conventional phototherapy (DSCP) is the
choice of treatment in severe hyperbilirubinemia in
some centers to maximize the efficacy of
phototherapy. However, no study in the literature
has compared the efficacy of high-intensity
phototherapy and DSCP. For this reason, in this
study we aimed to compare efficacy in infants who
received light emitting diode (LED) phototherapy
and DSCP.
Materials and Methods
Patients
One hundred twenty-three healthy term and
near term (≥35 weeks) infants requiring
phototherapy
for
non-hemolytic
hyperbilirubinemia were enrolled in the study. All
infants were appropriate for gestational age
(assumed to be the time measured from the first day
of the mother’s last menstrual cycle to the day of
birth), with normal Apgar scores and normal
findings on physical examination. Infants with
normal blood counts and peripheral blood smears,
no evidence of blood group iso-immunization,
negative result of a direct Coombs test, normal
reticulocyte count, and normal glucose-6-phosphate
dehydrogenize activity were eligible for the study.
Patients with any congenital malformation, direct
hyperbilirubinemia, enclosed hemorrhage, positive
338
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direct Coombs test, or infection were excluded. In
every patient, clinical assessment of gestational age
was performed using the Ballard scoring system.
Phototherapy
Criteria for phototherapy for healthy term and
near-term neonates were based on those of the 1994
American Academy of Pediatrics Practice
Parameter, as follows: <24 h: PTB 10 mg/dl (170
μmol/l); 24-48 h: 15 mg/dl (205 μmol/l); 49-72 h: 17
mg/dl (256 μmol/l); >72 h: 17 m/dl (291-308 μmol/l)
(4,5). All infants were exposed, completely
unclothed with their eyes and genital regions
covered, to continuous phototherapy, which was
interrupted only for feeding, cleaning, and blood
sampling. The infants’ weights and temperatures
were monitored. All infants’ gestational age, type of
feeding, age at phototherapy, TSB level at initiation
and termination of phototherapy, duration of
phototherapy, rebound TSB levels, and type of
phototherapy were recorded. The type of
phototherapy used was largely determined by the
neonatal staff, who tended to prefer LED for those
with rapidly increasing or with more severe jaundice
and standard phototherapy for the more usual
“standard” cases. Fifty-four patients received DSCP
(Group I) and 69 patients received LED (Group II).
In the DSCP group, 2 standard 25 W daylight
fluorescent lamps and 2 special blue fluorescent
lamps (Philips TL 20 W/52) were placed 35 cm over
the infants and a phototherapy mattress was placed
under the infants (Bilibed, Medela Medical
Technology, Baar, Switzerland). Light intensity was
measured by a Minolta 451 Fluoro-lite meter. The
lamps were changed regularly after 2000 h of use, by
which time the irradiance was 80% of the original. In
the intensive phototherapy the LED system
(Neoblue® LED phototherapy system, Natus Medical
Inc. San Carlos, CA, USA, intensity: 35 μW/cm2/nm,
spectrum 450-470 nm) was used. The system was
placed 30 cm over the infants. The intensity was
checked every 6 months by Ohmeda Biliblanket.
Laboratory measurements
Venous blood sampling was performed at the
start of phototherapy and 4 h thereafter, with the
lights switched off. Phototherapy was stopped when
bilirubin concentrations had decreased to <205
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μmol/l (12 mg/dl). The duration of phototherapy
was recorded.
The rebound protocol included rebound
bilirubin level determination 36 h (between 24 and
48 h) after the discontinuation of phototherapy.
Those neonates whose post-phototherapy TSB
concentrations were lower than those at the
discontinuation of phototherapy were discharged
from follow up. Rebound bilirubin level was
measured in patients followed up for 24-48 h
intervals until either stabilization or a decrease in the
TSB concentrations, if repeat TSB levels ≥ 239
μmol/l (≥14 mg/dl). Phototherapy was
recommenced at the discretion of the attending
neonatologist, but not usually at TSB values <256
μmol/l (15 mg/dl) (5). Infants with rebound
bilirubin values greater than or equal to
concentrations before phototherapy were again
exposed to phototherapy, following the same
guidelines as in the first exposure. Failure of
phototherapy was defined as continued increase in
bilirubin concentration in 2 consecutive
determinations beyond the starting bilirubin value.
The efficacy of phototherapy was assessed by the
duration of phototherapy (h), and the overall
decrease in bilirubin concentration related to the
total exposure time.
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Statistical analysis
Statistical analysis was carried out using
Student’s t-test and chi-square test and data are
expressed as mean ± SD.
Study ethics
The study was approved by the Fatih University
Ethics Committee and was conducted in accordance
with the ethical principles described by the
Declaration of Helsinki. Informed consent was
obtained from the infants’ parents before the study
commenced.
Results
Group I consisted of 54 patients (32 male and 22
female), whereas Group II included 69 patients (39
male and 30 female). There was no significant
difference in age distribution between the groups (P
> 0.05). The Table lists the clinical data and results of
the patients.
All the infants remained well during and after
exposure. All the infants were able to maintain
normothermia during phototherapy. Increased fluid
intake was needed to ensure adequate hydration in
Group II. During the study 3 newborns in the DSCP
group, and 2 newborns in the LED group had

Table. Clinical and laboratory data of study groups.
Group I
n = 54

Group II
n = 69

P value

Gestational age, weeks

37.7 ± 1.48

37.4 ± 4.1

NS

Birth weight, grams

3064 ± 416

3011 ± 453

NS

Age at phototherapy, hours

113 ± 26

117 ± 38

NS

Hematocrit, at the start of phototherapy

51 ± 6.3

52 ± 5

NS

Reticulocyte

2.1 ± 1.6

2 ± 1.1

NS
.001

TSB level at initiate of phototherapy, μmol/l (mg/dl)

317.9 ± 20.4 (18.7 ± 1.2)

340 ± 52.7(20 ± 3.1)

After 4 h of phototherapy, μmol/l (mg/dl)

295.8 ± 30.6 (17.4 ± 1.8)

301 ± 42.5 (17.7 ± 2.5)

NS

222.7 ± 22 (13.1 ± 1.3)

207.4 ± 27.2 (12.2 ± 1.6)

.002

26.6 ± 9.3

27.5 ± 15

NS

Rebound TSB level, μmol/l (mg/dl)

239.7 ± 20.4 (14.1 ± 1.2)

233 ± 34 (13.7 ± 2)

NS

Breastfed exclusively, number, (%)

37(69)

49(71)

NS

Breastfed plus formula, number, (%)

17(31)

20(29)

NS

TSB level at termination of phototherapy, μmol/l (mg/dl)
Duration of phototherapy

NS: Nonsignificant
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transient erythema, and 2 newborns in each group
had mild watery defecation not leading to
dehydration. No serious complications or side
effects were observed during the study.

No phototherapy failure was observed during
treatment in either group and phototherapy was
effective in decreasing bilirubin levels in both
groups, but the response was greater to the LED (P =
0.002). Although TSB level at the initiation of
phototherapy in Group II was higher than that in
Group I, duration of phototherapy was similar in the
groups (P > 0.05). TSB level at the initiation of
phototherapy in Group I was lower than that in
Group II, while it was higher in Group I than in
Group II at the termination of phototherapy [at the
initiation and 222.7 ± 22.1 μmol/l (13.1 ± 1.3 mg/dl)
and 207.4 ± 27.2 (12.1 ± 1.6 mg/dl) μmol/l at the
termination, respectively] (P = 0.002). However,
there was no significant difference in rebound TSB
levels between the 2 groups. A decrease in bilirubin
concentration occurred in all infants but was
especially marked in the infants exposed to LED
(Figure); by the discontinuous of phototherapy the
bilirubin concentration in Group II had decreased to
below the bilirubin concentration of Group I [71.4
μmol/l/24 h (4.2 mg/dl/24 h), 118.32 μmol/l/24 h
(6.9 mg/dl/24 h), respectively] (P < 0.05).

Total serum bilirubin levels under double conventional
and intensive phototherapies

20
TSB levels (mg/dl)

During the study period the average spectral
irradiances in the DSCP group were 18.7 ± 0.8
μW/cm2/nm and 30.1 ± 5.5 μW/cm2/nm in the LED
system.
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Light emitting diode phototherapy
Double conventional

Figure. Total serum bilirubin levels under double conventional and
intensive phototherapies.

Discussion
In this study of 123 infants LED was more
effective than DSCP in the treatment of
nonhemolytic hyperbilirubinemia. This occurred
despite lower initial bilirubin levels in the DSCP
group. Moreover, rebound bilirubin levels were
similar in the 2 groups. There is no previously
reported study that has specifically compared LED
phototherapy and DSCP in the clinical setting.

After the termination of the phototherapy, 4
newborns in the conventional phototherapy group
and 6 newborns in the LED group had increased
rebound bilirubin values ≥ 256 μmol/l (15 mg/dl).
This difference was not statistically significant but
the response was greater in the LED group (P >
0.05).

The DSCP system used in our study was similar
to the one used by Sarici et al. (6). They used a
combination of fiberoptic phototherapy plus
conventional phototherapy with a special blue light
that was found to be more effective in reducing
serum bilirubin levels than single conventional
phototherapy. Tan et al. found DSCP very
efficacious in preterm babies, and claimed that this
resulted from the skin properties of preterm babies
(7).

The infants tolerated the blue light well and no
behavioral difference was observed between the
infants exposed to white or blue light. Feeding was well
tolerated and no vomiting or irritability was observed
in either group.

Tan et al. also demonstrated that the maximum
average spectral irradiance level required to eliminate
bilirubin effectively by reaching a saturation point
occurs at doses of 40 μW/cm2/nm or higher (8).
Although the total average spectral irradiance of LED
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was 30 μW/cm2/nm in our LED group, which was
below the reported level, we obtained a satisfactory
and safe bilirubin reduction in the given time period.
Although DSCP was applied to a wider surface area,
LED was more effective. The greater efficacy of
phototherapy in this group was due to increases in
average spectral irradiance. As the average spectral
power increased consequently, it must have provided
effective bilirubin elimination by causing much more
lumirubin production (9).
More rebound was observed after LED, resulting
in a need for re-phototherapy that was about 5 times
more frequent than that in the daylight group (8).
This phenomenon is probably due to the duration of
LED being significantly shorter, with cessation of
phototherapy occurring at a period when the rate of
bilirubin accumulation was still appreciable; a level
still capable of reducing the efficacy of standard
daylight phototherapy ensured cessation at a later
stage when the rate of bilirubin accumulation was
probably already declining; hence the lower rebound
and need for a second exposure. Our study showed
that the post-phototherapy rebound was also mild in
LED; repeat treatment for those few needing a
second exposure was equally effective compared
with the conventional phototherapy.
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In our clinic we often prefer LED for those with
rapidly increasing or more severe jaundice and
standard phototherapy for the more usual
“standard” cases. Therefore there was a significant
difference between initial TSB levels.
There was no phototherapy failure in this study.
This may be due to the non-hemolytic nature of the
hyperbilirubinemia of our patients and the greater
efficacy of LED lamps in this study (1,10).
We observed no acute and severe side-effects, or
complications with LED. This was in agreement
with the study reported by Granati et al. (11). They
investigated whether high-dose phototherapy given
to newborns during the neonatal period would cause
any long-term negative effects on visual functions,
hearing, growth, and neurological developments of
patients at 6 year of age, and reported no difference
between the patients receiving high-dose
phototherapy and the control group receiving no
phototherapy (11).
In conclusion, light emitting diode phototherapy
should be considered for infants with especially
severe hyperbilirubinemia. This should also be the
case for those infants not responding to
conventional phototherapy lamps.
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